Compare BHM & POM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BHM | POM |
|---|---|---|
| Founded | 2022 | 2015 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Other Specialty Stores |
| Sector | Real Estate | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.9M | 38.8M |
| IPO Year | N/A | 2025 |
| Metric | BHM | POM |
|---|---|---|
| Price | $9.48 | $0.24 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $15.00 | N/A |
| AVG Volume (30 Days) | 7.3K | ★ 463.6K |
| Earning Date | 01-01-0001 | 12-03-2025 |
| Dividend Yield | ★ 5.55% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $74,462,000.00 | $51,210,721.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 27.95 | 12.13 |
| 52 Week Low | $8.05 | $0.21 |
| 52 Week High | $14.81 | $6.43 |
| Indicator | BHM | POM |
|---|---|---|
| Relative Strength Index (RSI) | 50.90 | 28.17 |
| Support Level | $8.60 | $0.21 |
| Resistance Level | $9.40 | $0.25 |
| Average True Range (ATR) | 0.43 | 0.03 |
| MACD | 0.01 | 0.07 |
| Stochastic Oscillator | 74.77 | 38.33 |
Bluerock Homes Trust Inc owns and operates a portfolio of institutional residential properties including single-family homes, build-to-rent communities, and other residential communities located in attractive markets with a focus on the knowledge-economy and high-quality of life growth markets of the Sunbelt and Western United States. The company's principal objective is to generate attractive risk-adjusted returns on investments where it believes it can drive growth in funds from operations and net asset value by acquiring residential units, developing residential communities, and through value-add renovations. The Company is an externally managed REIT managed and advised by Bluerock Homes Manager, LLC.
Pomdoctor Ltd is an online medical services platform for chronic diseases in China. With a focus on chronic disease management and pharmaceutical services, its business model forms a one-stop platform for medical services, which organically connects patients to doctors and pharmaceutical products. Its experience in tackling chronic diseases can be traced back to the launch of its platform on mobile devices. The company operates in two segments: Internet hospital, and Pharmaceutical supply chain. The majority of revenue is derived from the Pharmaceutical supply chain segment.